Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MINERVA SURGICAL INCUTRS · Entity 115564 | CFO | May 02, 2022 | August 09, 2022 |
| Renalytix plcRNLX · Entity 7446 | Interim Chief Financial Office | June 11, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MINERVA SURGICAL INC
Report date May 02, 2022 · Filed August 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,730 |
Reported balance
After 2022-05-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-02 · Grant · Acquired 60,198 · Balance 220,730 F1: 60,198 of the securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs will vests on May 16, 2023, and additional 25% of the RSUs will vest annually thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2: 24,500 of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs vest on on December 15, 2022, subject to the Reporting Person continuing as a service provider on such date. F3: 136,032 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on July 22, 2021 and with respect to one thirty-sixth of the remaining shares each month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 60,198 of the securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs will vests on May 16, 2023, and additional 25% of the RSUs will vest annually thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2: 24,500 of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs vest on on December 15, 2022, subject to the Reporting Person continuing as a service provider on such date.
F3: 136,032 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on July 22, 2021 and with respect to one thirty-sixth of the remaining shares each month thereafter.
Renalytix plc
Report date June 11, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2034-06-10 | Direct | 60,000 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 60,000 · Balance 60,000 F1: The exercise price is 0.1625 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.2067 using the Bank of England rate as of June 10, 2024 (1.00 pound sterling = $1.272). F2: One fourth (1/4th) of the shares subject to the option award shall vest on August 28, 2024, and the remaining shares shall vest in nine equal monthly installments thereafter, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 0.1625 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.2067 using the Bank of England rate as of June 10, 2024 (1.00 pound sterling = $1.272).
F2: One fourth (1/4th) of the shares subject to the option award shall vest on August 28, 2024, and the remaining shares shall vest in nine equal monthly installments thereafter, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2024 Filed Jun 13, 2024 20:15 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001415889-24-016663 · form4-06132024_040602.xml · derivative · entry 1 Jung Joel R · CIK 0001373488 · Interim Chief Financial Office 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2034-06-10 F1 · derivative.exercise_price: The exercise price is 0.1625 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.2067 using the Bank of England rate as of June 10, 2024 (1.00 pound sterling = $1.272). F2 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on August 28, 2024, and the remaining shares shall vest in nine equal monthly installments thereafter, subject to the Reporting Person's continuous service. Read SEC document |
| May 02, 2022 Filed Aug 9, 2022 21:23 UTC | MINERVA SURGICAL INC UTRS · Entity 115564 | GrantCommon Stock | 60,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045123 · doc4.xml · nonDerivative · entry 1 Jung Joel R · CIK 0001373488 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,730 F1 · shares: 60,198 of the securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs will vests on May 16, 2023, and additional 25% of the RSUs will vest annually thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · balance_after: 60,198 of the securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs will vests on May 16, 2023, and additional 25% of the RSUs will vest annually thereafter, subject to the Reporting Person continuing as a service provider through each such date. F2 · balance_after: 24,500 of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs vest on on December 15, 2022, subject to the Reporting Person continuing as a service provider on such date. F3 · balance_after: 136,032 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on July 22, 2021 and with respect to one thirty-sixth of the remaining shares each month thereafter. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 19:47 UTC | MINERVA SURGICAL INC UTRS · Entity 115564 | GrantCommon Stock | 24,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070444 · doc4.xml · nonDerivative · entry 1 Jung Joel R · CIK 0001373488 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,532 F1 · shares: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs vest on on December 15, 2022, subject to the Reporting Person continuing as a service provider on such date. F1 · balance_after: These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 100% of the RSUs vest on on December 15, 2022, subject to the Reporting Person continuing as a service provider on such date. F2 · balance_after: 136,032 shares were acquired pursuant to the exercise of an early-exercise option and remain subject to a right of repurchase by the Company, which shall lapse with respect to one-fourth of the shares on July 22, 2021 and with respect to one thirty-sixth of the remaining shares each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.